{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:45:25Z","timestamp":1793317525089,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11892-022-01485-w","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T18:02:54Z","timestamp":1657648974000},"page":"461-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Lipodystrophy for the Diabetologist\u2014What to Look For"],"prefix":"10.1007","volume":"22","author":[{"given":"Nivedita","family":"Patni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhimanyu","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"issue":"12","key":"1485_CR1","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220\u201334.","journal-title":"N Engl J Med"},{"key":"1485_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2147\/DMSO.S130810","volume":"10","author":"E Chiquette","year":"2017","unstructured":"Chiquette E, et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10:375\u201383.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"1485_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ahj.2014.12.021","volume":"169","author":"P Andre","year":"2015","unstructured":"Andre P, et al. Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A. Am Heart J. 2015;169(4):587\u201393.","journal-title":"Am Heart J"},{"issue":"2","key":"1485_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2337\/db19-0447","volume":"69","author":"C Gonzaga-Jauregui","year":"2020","unstructured":"Gonzaga-Jauregui C, et al. Clinical and Molecular prevalence of lipodystrophy in an unascertained large clinical care cohort. Diabetes. 2020;69(2):249\u201358.","journal-title":"Diabetes"},{"issue":"9","key":"1485_CR5","doi-asserted-by":"publisher","first-page":"e1002654","DOI":"10.1371\/journal.pmed.1002654","volume":"15","author":"MS Udler","year":"2018","unstructured":"Udler MS, et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. PLoS Med. 2018;15(9):e1002654.","journal-title":"PLoS Med"},{"issue":"9","key":"1485_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrendo.2015.123","volume":"11","author":"N Patni","year":"2015","unstructured":"Patni N, Garg A. Congenital generalized lipodystrophies--new insights into metabolic dysfunction. Nat Rev Endocrinol. 2015;11(9):522\u201334.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1485_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","volume":"82","author":"A Misra","year":"2003","unstructured":"Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore). 2003;82(2):129\u201346.","journal-title":"Medicine (Baltimore)"},{"issue":"169","key":"1485_CR8","first-page":"33","volume":"43","author":"MG Dunnigan","year":"1974","unstructured":"Dunnigan MG, et al. Familial lipoatrophic diabetes with dominant transmission. A new syndrome Q J Med. 1974;43(169):33\u201348.","journal-title":"A new syndrome Q J Med"},{"issue":"1","key":"1485_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","volume":"83","author":"A Misra","year":"2004","unstructured":"Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004;83(1):18\u201334.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1485_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ng880","volume":"31","author":"AK Agarwal","year":"2002","unstructured":"Agarwal AK, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet. 2002;31(1):21\u20133.","journal-title":"Nat Genet"},{"issue":"4","key":"1485_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/ng585","volume":"28","author":"J Magre","year":"2001","unstructured":"Magre J, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28(4):365\u201370.","journal-title":"Nat Genet"},{"issue":"4","key":"1485_CR12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1210\/jc.2007-1328","volume":"93","author":"CA Kim","year":"2008","unstructured":"Kim CA, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93(4):1129\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1485_CR13","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1172\/JCI38660","volume":"119","author":"YK Hayashi","year":"2009","unstructured":"Hayashi YK, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest. 2009;119(9):2623\u201333.","journal-title":"J Clin Invest"},{"issue":"24","key":"1485_CR14","doi-asserted-by":"publisher","first-page":"8901","DOI":"10.1073\/pnas.1408523111","volume":"111","author":"F Payne","year":"2014","unstructured":"Payne F, et al. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. Proc Natl Acad Sci U S A. 2014;111(24):8901\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1485_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/emmm.200900037","volume":"1","author":"O Rubio-Cabezas","year":"2009","unstructured":"Rubio-Cabezas O, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med. 2009;1(5):280\u20137.","journal-title":"EMBO Mol Med"},{"issue":"24","key":"1485_CR16","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1315496","volume":"370","author":"JS Albert","year":"2014","unstructured":"Albert JS, et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. N Engl J Med. 2014;370(24):2307\u201315.","journal-title":"N Engl J Med"},{"issue":"12","key":"1485_CR17","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.cjca.2014.09.007","volume":"30","author":"SM Farhan","year":"2014","unstructured":"Farhan SM, et al. A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy. Can J Cardiol. 2014;30(12):1649\u201354.","journal-title":"Can J Cardiol"},{"key":"1485_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1750-1172-8-106","volume":"8","author":"B Donadille","year":"2013","unstructured":"Donadille B, et al. Partial lipodystrophy with severe insulin resistance and adult progeria Werner syndrome. Orphanet J Rare Dis. 2013;8:106.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1485_CR19","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2337\/diacare.26.6.1819","volume":"26","author":"KL Herbst","year":"2003","unstructured":"Herbst KL, et al. Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care. 2003;26(6):1819\u201324.","journal-title":"Diabetes Care"},{"issue":"1","key":"1485_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/hmg\/9.1.109","volume":"9","author":"H Cao","year":"2000","unstructured":"Cao H, Hegele RA. Nuclear lamin A\/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000;9(1):109\u201312.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"1485_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/72807","volume":"24","author":"S Shackleton","year":"2000","unstructured":"Shackleton S, et al. LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy. Nat Genet. 2000;24(2):153\u20136.","journal-title":"Nat Genet"},{"issue":"1","key":"1485_CR22","first-page":"408","volume":"87","author":"AK Agarwal","year":"2002","unstructured":"Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab. 2002;87(1):408\u201311.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5675","key":"1485_CR23","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1126\/science.1096706","volume":"304","author":"S George","year":"2004","unstructured":"George S, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004;304(5675):1325\u20138.","journal-title":"Science"},{"issue":"8","key":"1485_CR24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1007487","volume":"364","author":"S Gandotra","year":"2011","unstructured":"Gandotra S, et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med. 2011;364(8):740\u20138.","journal-title":"N Engl J Med"},{"issue":"9","key":"1485_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ejmg.2014.06.006","volume":"57","author":"DA Dyment","year":"2014","unstructured":"Dyment DA, et al. Biallelic mutations at PPARG cause a congenital, generalized lipodystrophy similar to the Berardinelli-Seip syndrome. Eur J Med Genet. 2014;57(9):524\u20136.","journal-title":"Eur J Med Genet"},{"issue":"2","key":"1485_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1086\/341908","volume":"71","author":"G Novelli","year":"2002","unstructured":"Novelli G, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A\/C. Am J Hum Genet. 2002;71(2):426\u201331.","journal-title":"Am J Hum Genet"},{"issue":"16","key":"1485_CR27","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/hmg\/ddg213","volume":"12","author":"AK Agarwal","year":"2003","unstructured":"Agarwal AK, et al. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet. 2003;12(16):1995\u20132001.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"1485_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/ng.3103","volume":"46","author":"D Lessel","year":"2014","unstructured":"Lessel D, et al. Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features. Nat Genet. 2014;46(11):1239\u201344.","journal-title":"Nat Genet"},{"issue":"11","key":"1485_CR29","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1002\/ajmg.a.34249","volume":"155A","author":"R Cabanillas","year":"2011","unstructured":"Cabanillas R, et al. Nestor-Guillermo progeria syndrome: a novel premature aging condition with early onset and chronic development caused by BANF1 mutations. Am J Med Genet A. 2011;155A(11):2617\u201325.","journal-title":"Am J Med Genet A"},{"issue":"6937","key":"1485_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nature01629","volume":"423","author":"M Eriksson","year":"2003","unstructured":"Eriksson M, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423(6937):293\u20138.","journal-title":"Nature"},{"issue":"5628","key":"1485_CR31","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1126\/science.1084125","volume":"300","author":"A De Sandre-Giovannoli","year":"2003","unstructured":"De Sandre-Giovannoli A, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science. 2003;300(5628):2055.","journal-title":"Science"},{"issue":"11","key":"1485_CR32","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1002\/ajmg.a.33690","volume":"152A","author":"LM Graul-Neumann","year":"2010","unstructured":"Graul-Neumann LM, et al. Marfan syndrome with neonatal progeroid syndrome-like lipodystrophy associated with a novel frameshift mutation at the 3' terminus of the FBN1-gene. Am J Med Genet A. 2010;152A(11):2749\u201355.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"1485_CR33","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/ajmg.a.37115","volume":"167A","author":"A Garg","year":"2015","unstructured":"Garg A, et al. Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. Am J Med Genet A. 2015;167A(8):1796\u2013806.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"1485_CR34","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/ng.2670","volume":"45","author":"MN Weedon","year":"2013","unstructured":"Weedon MN, et al. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet. 2013;45(8):947\u201350.","journal-title":"Nat Genet"},{"issue":"2","key":"1485_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ajhg.2014.12.011","volume":"96","author":"A Masotti","year":"2015","unstructured":"Masotti A, et al. Keppen-Lubinsky syndrome is caused by mutations in the inwardly rectifying K+ channel encoded by KCNJ6. Am J Hum Genet. 2015;96(2):295\u2013300.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1485_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ajhg.2013.05.019","volume":"93","author":"C Thauvin-Robinet","year":"2013","unstructured":"Thauvin-Robinet C, et al. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am J Hum Genet. 2013;93(1):141\u20139.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1485_CR37","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ajhg.2010.10.031","volume":"87","author":"AK Agarwal","year":"2010","unstructured":"Agarwal AK, et al. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet. 2010;87(6):866\u201372.","journal-title":"Am J Hum Genet"},{"key":"1485_CR38","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.3389\/fimmu.2018.02142","volume":"9","author":"F Corvillo","year":"2018","unstructured":"Corvillo F, et al. Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy. Front Immunol. 2018;9:2142.","journal-title":"Front Immunol"},{"issue":"2","key":"1485_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0002-9343(99)00414-3","volume":"108","author":"A Garg","year":"2000","unstructured":"Garg A. Lipodystrophies. Am J Med. 2000;108(2):143\u201352.","journal-title":"Am J Med"},{"issue":"11","key":"1485_CR40","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1485_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/jhg.2013.107","volume":"59","author":"T Nolis","year":"2014","unstructured":"Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014;59(1):16\u201323.","journal-title":"J Hum Genet"},{"issue":"2","key":"1485_CR42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","volume":"51","author":"I Hussain","year":"2019","unstructured":"Hussain I, Patni N, Garg A. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. Pathology. 2019;51(2):202\u201312.","journal-title":"Pathology"},{"key":"1485_CR43","first-page":"503","volume":"83","author":"VC Pardini","year":"1998","unstructured":"Pardini VC, et al. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatrophic diabetes. J Clin Endocrinol Metab. 1998;83:503\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1485_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1651-2227.1996.tb14262.x","volume":"413","author":"M Seip","year":"1996","unstructured":"Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl. 1996;413:2\u201328.","journal-title":"Acta Paediatr Suppl"},{"key":"1485_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1651-2227.1996.tb14265.x","volume":"413","author":"J Westvik","year":"1996","unstructured":"Westvik J. Radiological features in generalized lipodystrophy. Acta Paediatr Suppl. 1996;413:44\u201351.","journal-title":"Acta Paediatr Suppl"},{"issue":"3","key":"1485_CR46","doi-asserted-by":"publisher","first-page":"501","DOI":"10.7326\/0003-4819-69-3-501","volume":"69","author":"JD Brunzell","year":"1968","unstructured":"Brunzell JD, Shankle SW, Bethune JE. Congenital generalized lipodystrophy accompanied by cystic angiomatosis. Ann Intern Med. 1968;69(3):501\u201316.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1485_CR47","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/BF00241817","volume":"21","author":"JL Fleckenstein","year":"1992","unstructured":"Fleckenstein JL, et al. The skeleton in congenital, generalized lipodystrophy: evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99m bone scintigraphy. Skelet Radiol. 1992;21(6):381\u20136.","journal-title":"Skelet Radiol"},{"issue":"10","key":"1485_CR48","first-page":"3077","volume":"80","author":"M Chandalia","year":"1995","unstructured":"Chandalia M, et al. Postmortem findings in congenital generalized lipodystrophy. J Clin Endocrinol Metab. 1995;80(10):3077\u201381.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1485_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJM197501022920108","volume":"292","author":"Anonymous","year":"1975","unstructured":"Anonymous. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-1975. N Engl J Med. 1975;292(1):35\u201341.","journal-title":"N Engl J Med"},{"issue":"2","key":"1485_CR50","first-page":"358","volume":"75","author":"A Garg","year":"1992","unstructured":"Garg A, et al. Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab. 1992;75(2):358\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1485_CR51","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","volume":"87","author":"WA Haque","year":"2002","unstructured":"Haque WA, et al. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87(5):2395\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1485_CR52","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1210\/jc.2009-1824","volume":"95","author":"B Antuna-Puente","year":"2010","unstructured":"Antuna-Puente B, et al. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency. J Clin Endocrinol Metab. 2010;95(3):1463\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1485_CR53","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/jmg.39.10.722","volume":"39","author":"L Van Maldergem","year":"2002","unstructured":"Van Maldergem L, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet. 2002;39(10):722\u201333.","journal-title":"J Med Genet"},{"issue":"10","key":"1485_CR54","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1210\/jc.2003-030855","volume":"88","author":"AK Agarwal","year":"2003","unstructured":"Agarwal AK, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab. 2003;88(10):4840\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11-12","key":"1485_CR55","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1515\/jpem-2012-0240","volume":"25","author":"V Upreti","year":"2012","unstructured":"Upreti V, et al. An unusual cause of delayed puberty: Berardinelli- Seip syndrome. J Pediatr Endocrinol Metab. 2012;25(11-12):1157\u201360.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2 Pt 2","key":"1485_CR56","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/AOG.0b013e31822cecf7","volume":"119","author":"M Maguire","year":"2012","unstructured":"Maguire M, et al. Pregnancy in a woman with congenital generalized lipodystrophy: leptin's vital role in reproduction. Obstet Gynecol. 2012;119(2 Pt 2):452\u20135.","journal-title":"Obstet Gynecol"},{"issue":"19","key":"1485_CR57","doi-asserted-by":"publisher","first-page":"7054","DOI":"10.1073\/pnas.1324025111","volume":"111","author":"M Jiang","year":"2014","unstructured":"Jiang M, et al. Lack of testicular seipin causes teratozoospermia syndrome in men. Proc Natl Acad Sci U S A. 2014;111(19):7054\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"1485_CR58","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1093\/hmg\/ddv156","volume":"24","author":"C Ebihara","year":"2015","unstructured":"Ebihara C, et al. Seipin is necessary for normal brain development and spermatogenesis in addition to adipogenesis. Hum Mol Genet. 2015;24(15):4238\u201349.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"1485_CR59","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1530\/EJE-21-0915","volume":"185","author":"AN Karhan","year":"2021","unstructured":"Karhan AN, et al. Biallelic CAV1 null variants induce congenital generalized lipodystrophy with achalasia. Eur J Endocrinol. 2021;185(6):841\u201354.","journal-title":"Eur J Endocrinol"},{"key":"1485_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-511X-7-3","volume":"7","author":"H Cao","year":"2008","unstructured":"Cao H, et al. Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids Health Dis. 2008;7:3.","journal-title":"Lipids Health Dis"},{"issue":"3","key":"1485_CR61","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-21-1243","volume":"186","author":"N Patni","year":"2022","unstructured":"Patni N, Hegele RA, Garg A. Caveolar dysfunction and lipodystrophies. Eur J Endocrinol. 2022;186(3):C1\u20134.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1485_CR62","first-page":"1776","volume":"85","author":"A Garg","year":"2000","unstructured":"Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 2000;85(5):1776\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1485_CR63","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1210\/jc.2018-01922","volume":"104","author":"N Patni","year":"2018","unstructured":"Patni N, et al. Regional body fat changes and metabolic complications in children with Dunnigan lipodystrophy-causing LMNA Variants. J Clin Endocrinol Metab. 2018;104(4):1099\u2013108.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1485_CR64","first-page":"170","volume":"84","author":"A Garg","year":"1999","unstructured":"Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 1999;84(1):170\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1485_CR65","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2337\/diacare.26.5.1350","volume":"26","author":"WA Haque","year":"2003","unstructured":"Haque WA, et al. Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety. Diabetes Care. 2003;26(5):1350\u20135.","journal-title":"Diabetes Care"},{"issue":"18","key":"1485_CR66","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1161\/01.CIR.103.18.2225","volume":"103","author":"RA Hegele","year":"2001","unstructured":"Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circulation. 2001;103(18):2225\u20139.","journal-title":"Circulation"},{"issue":"10","key":"1485_CR67","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1210\/jc.2015-2476","volume":"100","author":"N Patni","year":"2015","unstructured":"Patni N, et al. A novel syndrome of generalized lipodystrophy associated with pilocytic astrocytoma. J Clin Endocrinol Metab. 2015;100(10):3603\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1485_CR68","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bjd.18124","volume":"182","author":"N Haddad","year":"2020","unstructured":"Haddad N, et al. Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol. 2020;182(2):477\u201380.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1485_CR69","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.2337\/dc18-2535","volume":"42","author":"A Jehl","year":"2019","unstructured":"Jehl A, et al. Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes. Diabetes Care. 2019;42(10):2008\u201310.","journal-title":"Diabetes Care"},{"issue":"1","key":"1485_CR70","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1210\/jc.2008-1703","volume":"94","author":"DB Savage","year":"2009","unstructured":"Savage DB, et al. Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab. 2009;94(1):10\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1485_CR71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1210\/jc.2007-1856","volume":"93","author":"JY Park","year":"2008","unstructured":"Park JY, et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab. 2008;93(1):26\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"1485_CR72","first-page":"bcr-2018","volume":"2018","author":"R Kumar","year":"2018","unstructured":"Kumar R, et al. Acquired generalised lipodystrophy and type 1 diabetes mellitus in a child: a rare and implacable association. BMJ Case Rep. 2018;2018:bcr-2018.","journal-title":"BMJ Case Rep"},{"issue":"9","key":"1485_CR73","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1210\/js.2019-00069","volume":"3","author":"S Srinivasan","year":"2019","unstructured":"Srinivasan S, et al. A polygenic lipodystrophy genetic risk score characterizes risk independent of BMI in the diabetes prevention program. J Endocr Soc. 2019;3(9):1663\u201377.","journal-title":"J Endocr Soc"},{"issue":"1","key":"1485_CR74","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","volume":"19","author":"Y Handelsman","year":"2013","unstructured":"Handelsman Y, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19(1):107\u201316.","journal-title":"Endocr Pract"},{"issue":"12","key":"1485_CR75","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500\u201311.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1485_CR76","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1079\/BJN19780152","volume":"40","author":"AS Jackson","year":"1978","unstructured":"Jackson AS, Pollock ML. Generalized equations for predicting body density of men. Br J Nutr. 1978;40(3):497\u2013504.","journal-title":"Br J Nutr"},{"issue":"3","key":"1485_CR77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1249\/00005768-198023000-00009","volume":"12","author":"AS Jackson","year":"1980","unstructured":"Jackson AS, Pollock ML, Ward A. Generalized equations for predicting body density of women. Med Sci Sports Exerc. 1980;12(3):175\u201381.","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"1485_CR78","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.ijo.0800802","volume":"23","author":"CV Dezenberg","year":"1999","unstructured":"Dezenberg CV, et al. Predicting body composition from anthropometry in pre-adolescent children. Int J Obes Relat Metab Disord. 1999;23(3):253\u20139.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"7","key":"1485_CR79","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1210\/clinem\/dgaa137","volume":"105","author":"C Vasandani","year":"2020","unstructured":"Vasandani C, et al. Diagnostic value of anthropometric measurements for familial partial lipodystrophy, Dunnigan Variety. J Clin Endocrinol Metab. 2020;105(7)2132-2141.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1485_CR80","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1210\/jc.2003-032140","volume":"89","author":"ED Javor","year":"2004","unstructured":"Javor ED, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004;89(7):3199\u2013207.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1485_CR81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/cen.13732","volume":"89","author":"B Akinci","year":"2018","unstructured":"Akinci B, et al. Renal complications of lipodystrophy: a closer look at the natural history of kidney disease. Clin Endocrinol. 2018;89(1):65\u201375.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"1485_CR82","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2215\/CJN.01271005","volume":"1","author":"C Musso","year":"2006","unstructured":"Musso C, et al. Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin J Am Soc Nephrol. 2006;1(4):616\u201322.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1485_CR83","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMoa012437","volume":"346","author":"EA Oral","year":"2002","unstructured":"Oral EA, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"1485_CR84","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1542\/peds.2006-3165","volume":"120","author":"J Beltrand","year":"2007","unstructured":"Beltrand J, et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics. 2007;120(2):e291\u20136.","journal-title":"Pediatrics"},{"issue":"3","key":"1485_CR85","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1210\/jc.2011-2229","volume":"97","author":"V Simha","year":"2012","unstructured":"Simha V, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2012;97(3):785\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1485_CR86","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2014-4491","volume":"100","author":"T Diker-Cohen","year":"2015","unstructured":"Diker-Cohen T, et al. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015;100(5):1802\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1485_CR87","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1055\/s-0031-1301284","volume":"44","author":"A Luedtke","year":"2012","unstructured":"Luedtke A, et al. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series. Horm Metab Res. 2012;44(4):306\u201311.","journal-title":"Horm Metab Res"},{"issue":"12","key":"1485_CR88","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.1463-1326.2008.00978.x","volume":"10","author":"V Simha","year":"2008","unstructured":"Simha V, Rao S, Garg A. Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety. Diabetes Obes Metab. 2008;10(12):1275\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1485_CR89","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/dme.13527","volume":"34","author":"F Banning","year":"2017","unstructured":"Banning F, et al. Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist. Diabet Med. 2017;34(12):1792\u20134.","journal-title":"Diabet Med"},{"issue":"1","key":"1485_CR90","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13256-016-1175-1","volume":"11","author":"J Oliveira","year":"2017","unstructured":"Oliveira J, et al. Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports. J Med Case Rep. 2017;11(1):12.","journal-title":"J Med Case Rep"},{"issue":"10","key":"1485_CR91","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1210\/jc.2017-01235","volume":"102","author":"A Melvin","year":"2017","unstructured":"Melvin A, et al. Roux-en-Y gastric bypass surgery in the management of familial partial lipodystrophy type 1. J Clin Endocrinol Metab. 2017;102(10):3616\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1485_CR92","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11605-016-3300-2","volume":"21","author":"S Grundfest-Broniatowski","year":"2017","unstructured":"Grundfest-Broniatowski S, et al. Successful treatment of an unusual case of FPLD2: The role of Roux-en-Y gastric bypass-case report and literature review. J Gastrointest Surg. 2017;21(4):739\u201343.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"1485_CR93","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2337\/db14-0104","volume":"64","author":"K Kozusko","year":"2015","unstructured":"Kozusko K, et al. Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. Diabetes. 2015;64(1):299\u2013310.","journal-title":"Diabetes"},{"issue":"3","key":"1485_CR94","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2265.2011.04057.x","volume":"75","author":"A Ciudin","year":"2011","unstructured":"Ciudin A, et al. Successful treatment for the Dunnigan-type familial partial lipodystrophy with Roux-en-Y gastric bypass. Clin Endocrinol. 2011;75(3):403\u20134.","journal-title":"Clin Endocrinol"},{"issue":"11","key":"1485_CR95","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1381\/096089206778869988","volume":"16","author":"NM McGrath","year":"2006","unstructured":"McGrath NM, Krishna G. Gastric bypass for insulin resistance due to lipodystrophy. Obes Surg. 2006;16(11):1542\u20134.","journal-title":"Obes Surg"},{"issue":"6","key":"1485_CR96","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2337\/dc06-0130","volume":"29","author":"KM Utzschneider","year":"2006","unstructured":"Utzschneider KM, Trence DL. Effectiveness of gastric bypass surgery in a patient with familial partial lipodystrophy. Diabetes Care. 2006;29(6):1380\u20132.","journal-title":"Diabetes Care"},{"key":"1485_CR97","doi-asserted-by":"crossref","unstructured":"Mandel-Brehm C, et al. Autoantibodies to perilipin-1 define a subset of acquired generalized lipodystrophy. Diabetes. 2022; db211172 (online ahead of print).","DOI":"10.2337\/db21-1172"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-022-01485-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-022-01485-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-022-01485-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T09:17:43Z","timestamp":1659691063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-022-01485-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":97,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1485"],"URL":"https:\/\/doi.org\/10.1007\/s11892-022-01485-w","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"3 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.P. have no financial or non-financial interests that are directly or indirectly related to the work submitted for publication. A.G. consults for Amryt Pharma PLC and Regeneron and has received grant support from Amryt Pharma PLC, Regeneron, Quintiles, Akcea Pharmaceuticals, and Intercept Pharmaceuticals. A.G. is coholder of a patent for \u201cuse of leptin for treating human lipoatrophy and a method of determining predisposition to said treatment\u201d but receives no financial compensation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}